# FDA approves Mounjaro to lower heart-attack, stroke and cardiovascular death risk in adults with type 2 diabetes

Canonical page: https://technooptimist.io/stories/fda-approves-mounjaro-to-lower-heart-attack-stroke-and-cardiovascular-9bdb06e4
Date: 28 Aug 2026
About: [Eli Lilly](https://technooptimist.io/companies/eli-lilly.md) · [Tirzepatide (Mounjaro / Zepbound)](https://technooptimist.io/biotech/tirzepatide.md)
Original source: https://www.biopharminternational.com/view/fda-approves-mounjaro-to-lower-cardiovascular-risk-in-type-2-diabetes-based-on-surpass-cvot

The FDA approved tirzepatide (Mounjaro) to reduce major adverse cardiovascular events in adults with type 2 diabetes who are at high risk for them. The approval rests on SURPASS-CVOT, which compared tirzepatide with dulaglutide in more than 13,000 people.

## Key facts

- SURPASS-CVOT enrolled more than 13,000 participants and compared tirzepatide with dulaglutide (Trulicity), not with placebo.
- The hazard ratio for major cardiovascular events was 0.92 (95% CI 0.83 to 1.01): non-inferior to dulaglutide, but superiority was not shown.
- The new label adds cardiovascular risk reduction to Mounjaro's use for blood-sugar control.

---

The Techno Optimist tracks every frontier of technology, program by program: https://technooptimist.io/ (a Markdown version of any page: add .md to its URL; site map for agents: https://technooptimist.io/llms.txt).
Data API (JSON, realtime stream): https://technooptimist.io/developers. People read 5 pages free, then Reader $10/month; these Markdown pages are open to agents.